Avista Healthcare Public Acquisition Corp.
Status: Deal Closed
U=S+W
W=S/2@11.5
| IPO Proceeds, $M | $310.00M |
|---|---|
| IPO Date | Oct 11, 2016 |
| CEO | David Burgstahler |
| Left Lead | Credit Suisse |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24+[4] |
| IPO Sector |
Healthcare
Healthcare (North America or Europe) |
| IPO Geography | Global |
| Target Company | Organogenesis |
| Deal Announced | Aug 17, 2018 |
| Deal Size, $M | $673.00M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Dec 10, 2018 |
| Amendment Vote | TBD |
| Closing Date | Dec 11, 2018 |
Formerly AHPA
ORGO
ORGOW
| Price | $3.97 |
|---|---|
| Last closing price | $4.08 |
| H/L, today | $3.90 / $4.16 |
| H/L, 52-week | $1.80 / $4.50 |
| Volume, today | 763,590 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Avista Healthcare Public Acquisition Corp.:
- Structure and cap table
- 8 directors & officers
- 47 filings and events
- 2 underwriters
- 1 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Thompson Dean | 58 | Executive Chairman |
| David Burgstahler | 48 | President, CEO & Director |
| John Cafasso | 44 | CFO |
| Benjamin Silbert | 46 | General Counsel & Secretary |
| Håkan Björklund | 60 | Director |
| Charles Harwood | 63 | Director |
| Brian Markison | 57 | Director |
| Robert O'Neil | 66 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Credit Suisse | BR | 29,250,000 | units |
| I-Bankers Securities | 750,000 | ||
| 30,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.